ATAI Investor Day Presentation Deck

RL - 007 development: excellent PK, well tolerated with replicated cognitive signals atai LIFE SCIENCES Study HV PK Scopolamine Cognitive Challenge Peripheral Diabetic Neuropathy N=48 N=23 N=180 Phase 1 7 Day Multiple Dose DB Placebo, 4x ΧΟ Cognition Cognition Phase 2 Double Blind Placebo XO, 1 month, 5 month ext Cognition Excellent PK and CSF exposure >500 subjects exposed (9 prior Phase 1 and 2 studies) Safety to 6 month (300 mg TID) Multiple independent cognitive signals (30-80 mg dose range) Safety /PK ✓ ✓ ✓ Target Biphasic Engaged ✓ ✓ Cognitive improvements seen at the lowest doses in prior studies | 29

View entire presentation